Clinic
Khaled A. Tawansy, M.D., INC
Khaled A. Tawansy, M.D., INC was paid $3.95M by Medicaid between Jan 2018 and Nov 2024, across 20 billing codes. Its largest line is J0178, Injection, aflibercept, 1 mg — 43% of everything it billed.
33Billing provider infoKHALED A. TAWANSY, M.D., INC
LOS ANGELES, CA 90041
LOS ANGELES, CA 90041
33aNPI1477733822assigned 11/13/2007
33bProvider typeClinic/Center
28Total paid$3.95M
24GClaims32,570
24DCodes billed20
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinic/Center providers in California
Rank by total paid#98 of 504
Median peer was paid$102K
This provider vs. median39×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,326 | $87K | |
| 2019 | 3,960 | $183K | |
| 2020 | 5,050 | $382K | |
| 2021 | 5,975 | $718K | |
| 2022 | 4,369 | $753K | |
| 2023 | 4,206 | $956K | |
| 2024incomplete | 5,684 | $871K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 43% | 1,842 | 1,150 | $1.68M |
| 67028 | Intravitreal injection of a pharmacologic agent | 33% | 7,796 | 5,044 | $1.30M |
| J9035 | Injection, bevacizumab, 10 mg | 5.5% | 2,843 | 2,458 | $219K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.8% | 3,214 | 3,000 | $188K |
| 92134 | 4.1% | 5,745 | 5,099 | $162K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 3.9% | 2,640 | 2,405 | $152K |
| 76512 | 2.2% | 2,434 | 1,609 | $88K | |
| J2777 | Injection, faricimab-svoa, 0.1 mg | <1% | 52 | 48 | $36K |
| 92226 | <1% | 1,929 | 997 | $33K | |
| 92201 | <1% | 2,443 | 2,230 | $31K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 391 | 321 | $23K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 602 | 577 | $22K |
8 more codes
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 88 | $7K |
| 92225 | <1% | 300 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 81 | $2K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 13 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 80 | $1K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 18 | $299.30 |
| 92202 | <1% | 21 | $237.67 | |
| 92015 | Determination of refractive state | <1% | 38 | $181.85 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTAWANSY, KHALED (OPHTHALMOLOGY)
| Provider | Location | Paid |
|---|---|---|
| Golden State Eye Medical Group INC | Bakersfield, CA | $11.19M |
| Raymond Renaissance Surgery Center LLC | Pasadena, CA | $197K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.